

STATUS AND PROSPECTS OF NATIVE PRODUCTION OF DRUGS IN KAZAKHSTAN

Asanhodzhaeva A.F., Korabel T.V., Shopabaeva A.R., Khimenko S.V.

The Kazakh National Medical University named after S.D. Asfendiyarov,
Almaty, Kazakhstan

National University of Pharmacy, Kharkiv, Ukraine

tanya_roza@mail.ru

Creation of national pharmaceutical industry, increase profitability and competitiveness of existing plants, the earliest increase in the share of native production of drugs to 50% by 2017, identified as top priorities for economic development.

The purpose of this research is to analyze the current state of the native production of medicines.

Assessment of the real level of development of the pharmaceutical industry was carried out on the basis of data from the State register of medicines in Kazakhstan as of February 19, 2013. The list of registered drugs of Kazakh production, was noted accounting for 12% of the total number of positions of the nomenclature in the specified register.

Currently there are about 79 domestic manufacturers of medicines. The main production is concentrated in eight major Kazakh refineries, which account for 74%. The largest portion of the plant is «Santo.Member of Polpharma Group» -29%, while the share of other “Kyzylmay”, “Shansharov-farm”, “Nobel”, “Romat”, “Global Pharm”, “Zerde-phyto”, “Dosfarm” is in band reception 3-10%. Besides investigating the manufacturers, we have analyzed the range of medicines and dosage forms revealed that the highest percentage of the production comes from such dosage forms such as tablets and solutions (31.2% and 18.1%, respectively), and the minimum - syrups and sprays (2.4% and 2.8%, respectively).

Thus, in the pharmaceutical market in Kazakhstan slow growth of domestic production is being observed. Performance of the raised task on increasing native produced medicines to 50% by 2017, while maintaining a similar rate of growth is problematic.

Necessary to implement a set of measures to enhance the system of national pharmaceutical industry as due to the significant expansion of the above eight leading enterprises and the creation of new businesses that meet modern requirements and drug manufacturers.